Fig. 1: CD123 CAR T cells demonstrate anti-leukemic effects in MOLM-13 AML xenograft mice.

a Schematic diagram summarizing the experimental plan for the MOLM-13^Luc AML xenograft model using Rag2^−/−Il2rγ^−/− recipients. b Kaplan–Meier analysis demonstrating percentage survival of AML^MOLM-13-bearing mice treated with PBS (n = 15), non-transduced T cells (NTD) (n = 15), or anti-CD123 CAR T cells (n = 16). Data were pooled from three independent experiments. p-value was calculated using the two-sided Mantel–Cox (log-rank) test. Attrition of mice was due to paralysis in both hind legs, growth of subcutaneous tumors (>2 cm), or BLI-detectable AML progression in the head. c Representative serial BLI images from three independent experiments depicting leukemia burden of MOLM-13 engrafted mice treated with PBS, NTD Tc or anti-CD123 CAR Tc. Data are represented colorimetrically (photons s⁻¹ cm⁻¹) with the scale bars indicating upper (max) and lower (min) BLI thresholds at each analysis time point. d Quantification of the BLI signal at the indicated time points for each treatment group. Data was pooled from two independent experiments, and represented as mean ± SEM for each treatment group (PBS n = 10; NTD Tc n = 12; anti-CD123 CAR Tc n = 12). On day 35, at least 5 mice per group were still alive and included in the analysis. e Representative flow cytometry-gating strategy for total human CD45, residual MOLM-13 CD123⁺ leukemia cells as well as residual CD4⁺/CD8⁺ T cells from the BM of mice treated with PBS, NTD Tc or anti-CD123 CAR Tc Flow cytometric analysis depicting absolute counts (cells/μL) of live residual f human CD45⁺ and g hCD45⁺ CD3⁻ CD123⁺ leukemia cells in the BM of PBS (n = 8), NTD Tc (n = 8) or anti-CD123 CAR Tc (n = 8) treated mice. Data were pooled from two independent experiments and represented as mean absolute cell counts ± SEM for each treatment group. p-values for f and g were calculated using two-sided one-way ANOVA (Kruskal–Wallis test with Dunn’s multiple comparisons).